九强生物
(300406)
| 流通市值：56.02亿 | | | 总市值：77.66亿 |
| 流通股本：4.24亿 | | | 总股本：5.88亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,237,396,355.82 | 821,722,324.81 | 393,894,885.38 | 1,741,626,675.37 |
| 营业收入 | 1,237,396,355.82 | 821,722,324.81 | 393,894,885.38 | 1,741,626,675.37 |
| 二、营业总成本 | 793,399,425.93 | 518,454,199.71 | 252,157,863.84 | 1,152,367,616.41 |
| 营业成本 | 274,578,957.58 | 186,299,645.98 | 91,143,372.7 | 441,259,980.15 |
| 税金及附加 | 11,938,565.26 | 7,278,214.32 | 3,668,591.43 | 14,968,576.3 |
| 销售费用 | 240,932,669.56 | 147,674,341.51 | 69,720,757.44 | 364,053,463.81 |
| 管理费用 | 105,307,615.95 | 69,914,142.33 | 34,075,533.29 | 126,984,292.29 |
| 研发费用 | 129,511,221.98 | 86,944,037.45 | 42,889,988.58 | 162,898,782.94 |
| 财务费用 | 31,130,395.6 | 20,343,818.12 | 10,659,620.4 | 42,202,520.92 |
| 其中:利息费用 | 35,441,089.73 | 23,380,926.38 | 11,796,810.8 | 46,992,080.57 |
| 其中:利息收入 | 4,752,693.99 | 3,414,971.12 | 1,563,513.65 | 5,187,911.35 |
| 加:投资收益 | 1,725,900.91 | 1,398,418.93 | 1,115,166.92 | 20,763,691.84 |
| 资产处置收益 | -2,201,612.67 | -1,247,038.46 | -290,627.64 | -3,495,156.98 |
| 资产减值损失(新) | 0 | 0 | 0 | -3,746,940.6 |
| 信用减值损失(新) | -6,781,439.51 | -6,782,017.91 | 90,000 | -26,744,200.79 |
| 其他收益 | 6,937,950.17 | 6,007,446 | 1,728,678.63 | 17,839,934.79 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 443,677,728.79 | 302,644,933.66 | 144,380,239.45 | 593,876,387.22 |
| 加:营业外收入 | 68,893.27 | 22,857.28 | 15,714.3 | 81,447.96 |
| 减:营业外支出 | 2,213,723.09 | 2,092,835.03 | 1,988,002.82 | 403,271.12 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 441,532,898.97 | 300,574,955.91 | 142,407,950.93 | 593,554,564.06 |
| 减:所得税费用 | 69,130,619.97 | 50,987,663.65 | 22,188,466.89 | 71,484,904.19 |
| 六、净利润 | 372,402,279 | 249,587,292.26 | 120,219,484.04 | 522,069,659.87 |
| 持续经营净利润 | 372,402,279 | 249,587,292.26 | 120,219,484.04 | 522,069,659.87 |
| 归属于母公司股东的净利润 | 373,384,271.63 | 250,373,606.97 | 120,648,449.77 | 523,742,821.32 |
| 少数股东损益 | -981,992.63 | -786,314.71 | -428,965.73 | -1,673,161.45 |
| (一)基本每股收益 | 0.63 | 0.43 | 0.21 | 0.9 |
| (二)稀释每股收益 | 0.63 | 0.43 | 0.21 | 0.88 |
| 八、其他综合收益 | -163,841.94 | 110,421.36 | 37,868.49 | 218,516.48 |
| 归属于母公司股东的其他综合收益 | -135,197.27 | 85,240.64 | 27,198.35 | 160,849.98 |
| 九、综合收益总额 | 372,238,437.06 | 249,697,713.62 | 120,257,352.53 | 522,288,176.35 |
| 归属于母公司股东的综合收益总额 | 373,249,074.36 | 250,458,847.61 | 120,675,648.12 | 523,903,671.3 |
| 归属于少数股东的综合收益总额 | -1,010,637.3 | -761,133.99 | -418,295.59 | -1,615,494.95 |
| 公告日期 | 2024-10-29 | 2024-08-23 | 2024-04-29 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |